Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms.
- Author:
Wei HE
1
;
Yanming XIE
;
Yongyan WANG
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. hewei7826@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
China;
Clinical Trials as Topic;
Drug Therapy;
standards;
Drug-Related Side Effects and Adverse Reactions;
Drugs, Chinese Herbal;
adverse effects;
standards;
therapeutic use;
Humans;
Product Surveillance, Postmarketing
- From:
China Journal of Chinese Materia Medica
2010;35(11):1498-1500
- CountryChina
- Language:Chinese
-
Abstract:
Re-evaluation of premarketing medicine is a important supplementary of clinical and elementary research. It is a basement that establish the medicine administration supervisition , found and integrity postmarketing washing out mechanism and define reasonable using drug. After drug marketing, we must not only concern on the re-evaluation of herbs security but also focus on evaluating herbs suitable symptom, as well as its dosage and course of treatment, ect. The re-evaluation of symptoms were seen as the core and feature of traditional Chinese medicine's clinical evaluation. It is also seen as hot spot and difficulty of the research . This article try to focus on simply illustrating the necessity and research thinking of re-evaluation symptoms of postmarketing herbs. So we can define the re-evaluation of postmarketing drug's objection, method, and basement. It will provide beneficial experience and reference to re-evaluation symptom of marketed herbs.
